Tumor Size and Serum Chromogranin A Levels Predict Metastatic Disease on DOTATATE Imaging

Larger tumor size and elevated serum chromogranin A levels are predictive of metastatic disease in patients with gastroenteropancreatic neuroendocrine tumors undergoing DOTATATE imaging. Patients with primary tumor size ≥2 cm, serum CGA level ≥150 ng/ml, and tumor grade g2 are at higher risk of metastases, indicating the potential use of these factors in identifying patients who would benefit from DOTATATE imaging for complete staging.